CCR7 and melanoma: Profiting from the amplified expression of CCR7, DCs pretreated with thyroid hormone triiodothyronine or allogeneic melanoma-derived cell lysate can move to dLNs and stimulate antigen-specific cytotoxic T-cell responses more effectively after being injected into melanoma animal models (Gonzalez et al., 2014; Alamino et al., 2015).